SAN FRANCISCO, April 14, 2022 /PRNewswire/ -- The global diabetic retinopathy market size is expected to reach USD 13.8 billion by 2030 registering a CAGR of 6.4%, according to a new report by Grand View Research, Inc. The incidence rate of diabetes has been increasing dramatically. According to the International Diabetes Federation, in 2021 there were about 537 million diabetic cases, which is projected to rise to 643 million by 2030 and 783 million by 2045. Diabetes is among the leading cause of blindness in people. Blindness is caused due to leaking or rupturing of retinal blood vessels, which may be permanent or temporary in nature depending on the disease stage. Studies suggest that in 2020 the number of diabetic retinopathy cases were about 103.12 million; the cases are expected to reach 160.5 million by 2045.
Key Insights & Findings from the report:
- The non-proliferative diabetic retinopathy segment accounted for the largest revenue share, by type, in 2021. The presence of a large number of patients within the bracket of fewer than 10 years of diabetic history contributed to the large size of this segment.
- The anti-VEGF segment accounted for the largest revenue share, by management, in 2021. The high applicability of these drugs in the treatment and early diagnosis of mild to moderate cases of non-proliferative DR treatment is among the prime factors leading to segmental growth.
- In Asia Pacific, the market is expected to witness the highest CAGR over the forecast period. The large population base in this region, high prevalence of diabetes, and rising geriatric population are likely to bolster the market.
Read 120-page market research report, "Diabetic Retinopathy Market Size, Share & Trends Analysis Report By Type (Proliferative DR, Non-proliferative DR), By Management (Anti-VEGF Therapy, Intraocular Steroid Injection, Laser Surgery, Vitrectomy), By Region, And Segment Forecasts, 2022 - 2030", published by Grand View Research.
Diabetic Retinopathy Market Growth & Trends
Rising patient awareness levels and increasing healthcare expenditure are also among the factors which are likely to propel market growth. Moreover, the increasing geriatric population in both developed and developing nations is expected to propel the market over the forecast period. According to the Population Reference Bureau report titled "Aging in the United States", the number of people in the U.S. aged 65 years and over was projected to increase from around 46 million in 2016 to over 98 million by 2060. Early detection and treatment guidelines for diabetic retinopathy had significantly reduced due to the COVID-19 pandemic-related constraints. When compared to 2019, intravitreal injections for diabetic retinopathy had decreased significantly globally throughout the pandemic, ranging from around 30 to over 100 percent reduction. However, now that the lockdown restrictions have been removed, the market is expected to grow at a significant rate.
Diabetic Retinopathy Market Segmentation
Grand View Research has segmented the global diabetic retinopathy market based on type, management, and region:
Diabetic Retinopathy Type Outlook (Revenue, USD Million, 2018 - 2030)
- Proliferative diabetic retinopathy
- Non-proliferative diabetic retinopathy
Diabetic Retinopathy Management Outlook (Revenue, USD Million, 2018 - 2030)
- Anti-VEGF
- Intraocular steroid injection
- Laser surgery
- Vitrectomy
Diabetic Retinopathy Regional Outlook (Revenue, USD Million, 2018 - 2030)
- North America
- U.S.
- Canada
- Europe
- U.K.
- Germany
- France
- Italy
- Spain
- Asia Pacific
- Japan
- China
- India
- South Korea
- Thailand
- Latin America
- Brazil
- Mexico
- Argentina
- Colombia
- Middle East and Africa
- South Africa
- Saudi Arabia
- UAE
List of Key Players of Diabetic Retinopathy Market
- Bayer AG
- Allergan plc
- Novartis AG
- Oxurion NV
- Sirnaomics Inc.
- Genentech
- Alimera Sciences
- Ampio Pharmaceuticals
- BCN Peptides
- Kowa Company, Ltd.
Check out more related studies published by Grand View Research:
- Diabetes Associated Ophthalmic Treatment Market - The global diabetes associated ophthalmic treatment market size is expected to reach USD 44.7 billion by 2028, according to a new report by Grand View Research, Inc. The market is expected to expand at a CAGR of 6.5% from 2021 to 2028. The increasing prevalence of type II diabetes, geriatric population, and availability of early detection techniques are some of the factors driving the growth.
- Vitrectomy Devices Market - The global vitrectomy devices market size is expected to reach USD 1.7 billion by 2028. The market is expected to expand at a CAGR of 6.2% from 2021 to 2028. The growing prevalence of diabetes is expected to drive the probability of diabetic retinopathy, thus, contributing to market growth. Additionally, the growing demand for vitrectomy due to its associated advantages for providing support to other ophthalmic surgeries is also expected to boost the market growth.
- Ophthalmic Photocoagulator Market - The global ophthalmic photocoagulator market size is expected to reach USD 213.2 million by 2028, according to a new report by Grand View Research, Inc. The market is expected to expand at a CAGR of 4.7% from 2021 to 2028. The global influence of COVID-19 on eye health and the rise in the incidence of increasing ocular diseases, such as diabetic retinopathy and age-related macular edema, are the key factors fuelling the market growth.
Browse through Grand View Research's Medical Devices Industry Research Reports.
About Grand View Research
Grand View Research, U.S.-based market research and consulting company, provides syndicated as well as customized research reports and consulting services. Registered in California and headquartered in San Francisco, the company comprises over 425 analysts and consultants, adding more than 1200 market research reports to its vast database each year. These reports offer in-depth analysis on 46 industries across 25 major countries worldwide. With the help of an interactive market intelligence platform, Grand View Research Helps Fortune 500 companies and renowned academic institutes understand the global and regional business environment and gauge the opportunities that lie ahead.
Contact:
Sherry James
Corporate Sales Specialist, USA
Grand View Research, Inc.
Phone: 1-415-349-0058
Toll Free: 1-888-202-9519
Email: sales@grandviewresearch.com
Web: https://www.grandviewresearch.com
Grand View Compass | Grand View Pipeline
Follow Us: LinkedIn | Twitter
Logo: https://mma.prnewswire.com/media/661327/Grand_View_Research_Logo.jpg
Share this article